Clinical Implications of the ISCHEMIA Trial: Invasive vs Conservative Approach in Stable Coronary Disease.
Jamal ChoudharySarah ChiuPriyanka BhugraBehnood BikdeliAzhar SupariwalaRajiv JauharSaurav ChatterjeePublished in: Current cardiology reports (2021)
Previous studies have shown inconsistent benefit of early angiography and revascularization in patients with stable ischemic heart disease. The ISCHEMIA trial showed no significant reduction in mortality or cardiovascular outcomes in patients undergoing early angiography and revascularization with guideline-directed medical therapy compared to patients on medical therapy alone in specific patient population with stable coronary artery disease. The ISCHEMIA trial provides insights into invasive versus pharmacological treatment for patients with stable ischemic heart disease. Though it may have reduced applicability given its broad exclusion criteria, it offers useful information about the utility of non-invasive imaging modalities for selecting optimal revascularization candidates.
Keyphrases
- coronary artery disease
- percutaneous coronary intervention
- coronary artery bypass grafting
- phase iii
- study protocol
- patients undergoing
- optical coherence tomography
- clinical trial
- phase ii
- end stage renal disease
- healthcare
- cardiovascular events
- computed tomography
- ejection fraction
- chronic kidney disease
- newly diagnosed
- coronary artery
- peritoneal dialysis
- randomized controlled trial
- acute coronary syndrome
- cardiovascular disease
- heart failure
- aortic stenosis
- open label
- case report
- type diabetes